Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BARDA grants $21m to Vaxin for anthrax vaccine
The funding will also support the company in conducting a first-in-man dose ranging study to evaluate the anthrax vaccine. Vaxin president and CEO Bill Enright said this is
The funding will also support the company in conducting a first-in-man dose ranging study to evaluate the anthrax vaccine. Vaxin president and CEO Bill Enright said this is
The study aimed to establish whether the immunogenicity of two doses of Heplisav was non-inferior/superior to three doses of Engerix-B by comparing seroprotection rates (SPRs) at eight weeks
ACZ885 is a fully human monoclonal antibody that inhibits IL-1 beta, which is an important part of the body’s immune system defenses In the study, ACZ885 was generally
The trial results showed BMD at the lumbar spine and total hip increased on average by 16.8% and 6.9% in comparison to baseline, respectively. The Phase 2 extension
The company’s decision is backed by the company’s growth in the healthcare inductry from its origins in prescription drug pricing and purchasing technology to its expansion into broader
Researchers used the Roche’s cardio instrument to carry out dose-response profiling of 60 pharmaceutical drugs including the drugs withdrawn from the market due to TdP arrhythmia, hERG trafficking
Hiroshi Yamazaki has joined as a regional director of EvaluatePharma Japan KK, who will be responsible for development of EvaluatePharma’s business in Japan. EvaluatePharmaAlpha offers an off-the-shelf valuation
The rise was mainly attributable to year-over-year increase in average selling prices of the company’s products and the growing market acceptance of the Company’s new products introduced in
The new R&D center will house two of Covidien’s emerging market R&D organizations, Tailored Products and Breakthrough Platforms. Covidien China R&D vice president Dong Wu said they will
Factor VIIa is used to treat hemophilia A and B patients who have developed inhibitors against treatment with either Factor VIII or IX and are suferring from acute